- Open Access
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials
© The Author(s). 2018
- Received: 21 September 2018
- Accepted: 21 September 2018
- Published: 1 October 2018
The original article was published in BMC Urology 2018 18:77
It has been highlighted that in the original article  there was a typesetting mistake in the Results – NNT in Strive section. This Correction article states the incorrect and correct sentence.
The NNT for rPFS at 2 year was 2.6 (upper, lower limits: 1.9, 4.0) and at 2 years was 3.0 (1.9, 7.2) when comparing enzalutamide and bicalutamide.
The NNT for rPFS at 1 year was 2.6 (upper, lower limits: 1.9, 4.0) and at 2 years was 3.0 (1.9, 7.2) when comparing enzalutamide and bicalutamide.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.